Molecular Classification-based identification of diagnostic and treatment targets in glioma

Adult glioma is a classic example that intensive research efforts in the areas of genomic sequencing, targeting genomic and epigenetic abnormalities have not identified subtype-specific pathways of pathogenesis and targetable vulnerabilities. A major source of this dilemma is that current classification standard, though prognostically relevant under the existing treatment options, fails to assign gliomas into biologically distinct entities. Transcriptome-based classification may integrate the effects between cell of origin and driving genomic alterations, and assign gliomas into distinct biology entities exhibiting biology-driven clinical manifestations. Thus, transcriptome-based subtyping may enable the identification of subtype-specific vulnerabilities. We hypothesize that key signaling pathways converged between neural development and gliomagenesis, and gene networks spanning these pathways might enable molecular classification of gliomas.

Key Notes

Despite detailed characterization of genomic alterations, subtype-specific vulnerabilities and treatment options in gliomas are hitherto not identified.

Based on the known developmental pathways converged between brain development and glioma, we developed an EM/PM classification scheme independent of morphological subtypes and grades.

While genetic makeup may change during glioma progression and/or across different tumor areas, developmentally anchored EM/PM subtypes are highly stable and contain subtype-specific vulnerabilities.

In this webinar, you will learn

Webinar Details

  • Date: Dr. Xiaolong Fan, professor at Beijing Normal University, China
  • Time: 18th November 2021
  • Speaker: 11:00 CET / 10:00 BST

Speaker-related Webinars